Intranasal ELI 200 Human Abuse Liability (HAL) trial: A double-blind, randomised 5-way crossover study
Phase of Trial: Phase I
Latest Information Update: 09 May 2016
At a glance
- Drugs ELI 200 (Primary) ; ELI 200 (Primary) ; Oxycodone
- Indications Opioid abuse
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Elite Pharmaceuticals
- 09 May 2016 Pharmacodynamic data assessing the abuse potential will be presented at the American Pain Society 35th Annual Scientific Meeting 2016, according to an Elite Pharmaceuticals media release.
- 17 Sep 2014 New trial record
- 09 Sep 2014 Primary endpoint has been met. (the peak effect (E max ) for Drug Liking).